文献速递姑息放疗与转移瘤放疗物理与技术

立体定向体部放疗再照射骨转移的前瞻性评估

Prospective Evaluation of Stereotactic Body Radiation Therapy for Reirradiation of Bone Metastases.
PubMed 文献 · Adv Radiat Oncol · 2025-12-12

这项前瞻性多机构2期试验纳入45例既往照射区域骨转移患者,2017年2月至2021年11月接受SBRT。主要终点为放疗后6个月局部控制,42/45部位局部控制,2年局部无进展率89.9%,2年总生存52%,急慢性毒性均为1-2级。

要点

  • 6个月时42/45个治疗部位局部控制,3个进展中位时间3.6个月。
  • 2年局部无进展率89.9%,2年总生存率52%。
  • 急性毒性46.7%、慢性毒性8.9%,均为1-2级,无脊髓病。

核心结论

  • SBRT再照射骨转移显示有效局部控制和合理急慢性毒性率。

研究设计与样本

  • 前瞻性多机构2期试验,45例既往照射区域骨转移患者于2017年2月至2021年11月接受SBRT。

主要发现

  • 中位年龄62.6岁,男性75.6%,最常见原发肿瘤为前列腺28.9%、肺17.8%、肾细胞11.1%。
  • 77.7%再照射部位为脊柱病灶,最常见剂量方案为30 Gy/5次53.3%和35 Gy/5次24.4%。
  • 6个月时42/45部位局部控制,3部位进展中位时间3.6个月。
  • 2年局部无进展率89.9%,2年总生存率52%。
  • 急性毒性46.7%最常见疲乏、恶心和疼痛 flare,慢性毒性8.9%包括椎体骨折和疼痛 flare,均为1-2级,无脊髓病。

关键数值与推荐

  • 主要终点为放疗后6个月局部控制。
  • 最常见剂量方案为30 Gy分5次和35 Gy分5次。
  • 2年局部无进展率89.9%,2年总生存率52%。

临床怎么用

  • 对既往照射区域骨转移可考虑SBRT再照射以获局部控制并限制危及器官剂量。
  • 常见急性毒性为1-2级疲乏、恶心和疼痛 flare,慢性毒性包括椎体骨折和疼痛 flare。

局限性

  • 需进一步研究长期疗效和治疗相关毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bone metastases are a common cause of morbidity among patients with cancer, and radiation therapy (RT) is efficacious for their palliation. However, symptomatic bone metastases can often occur in regions that have received prior RT, limiting doses that can be delivered safely. Stereotactic body radiation therapy (SBRT) enables the delivery of greater doses of RT to the tumor while minimizing reirradiation dose to critical organs at risk. METHODS AND MATERIALS: In this prospective, multi-institutional phase 2 trial, 45 patients with bone metastasis in a previously irradiated region were treated with SBRT from February 2017 to November 2021. The primary endpoint was local control at 6 months post RT; secondary aims were rates of acute and chronic toxicity, time to local progression, local progression rate, progression-free survival, and overall survival. RESULTS: The median age of participants was 62.6 years, and most were male (75.6%). The most common primary tumor types were as follows: prostate (13/45, 28.9%), lung (8/45, 17.8%), and renal cell (5/45, 11.1%). The majority received reirradiation to a spinal lesion (35/45, 77.7%). The most common dose prescriptions were 30 Gy in 5 fractions (24/45, 53.3%) and 35 Gy in 5 fractions (11/45, 24.4%). At 6 months, 42 of 45 treated sites were locally controlled, whereas 3 had progressed at a median of 3.6 months. The local progression-free rate was 89.9% at 2 years. Overall survival was 52% at 2 years. Acute toxicities occurred in 46.7%, most commonly fatigue, nausea, and pain flare; all were grade 1 or 2. In total, 8.9% of participants experienced chronic toxicities, including vertebral fracture and pain flare, all grade 1 or 2 with no myelopathies. CONCLUSIONS: This prospective study of SBRT for reirradiation of bone metastases demonstrated effective local control and reasonable rates of acute and chronic toxicities. Additional research is needed to further ascertain long-term efficacy and treatment-related toxicities.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hammoudeh L, Shin KY, Hertan L, et al. Prospective Evaluation of Stereotactic Body Radiation Therapy for Reirradiation of Bone Metastases. Adv Radiat Oncol. 2025. PMID: 41737978. doi:10.1016/j.adro.2025.101886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。